Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Downgrades Genmab to Neutral

Guggenheim analyst Michael Schmidt downgrades Genmab (NASDAQ:GMAB) from Buy to Neutral.

byBenzinga Newsdesk

January 3, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Genmab (NASDAQ:GMAB) from Buy to Neutral.

AnPac Bio Announces Plan To Implement ADS Ratio Change From 1:1 To 1:20

By Benzinga Newsdesk

Today, 10:58 AM

Philadelphia PA, October 18, 2022 – AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and

ANPC

Legal
News

Activision Blizzard Provides Update On Workplace Initiatives

By Bill Haddad

Today, 10:58 AM

Company Continues to Work with Regulators to Resolve and Address Workplace Issues Activision Blizzard, Inc. (NASDAQ:ATVI) said today that it continues to work with regulators on addressing and resolving workplace

ATVI

Price Over Earnings Overview: Crane

By Benzinga Insights

Today, 10:58 AM

Why PayPal Shares Are Falling Today

By Adam Eckert

Today, 10:58 AM

PayPal Holdings Inc (NASDAQ: PYPL) is trading lower Tuesday after the company announced worse-than-expected third-quarter revenue results and issued guidance below estimates.

PYPL

Guggenheim Downgrades Genmab to Neutral

Related Posts

AnPac Bio Announces Plan To Implement ADS Ratio Change From 1:1 To 1:20

Activision Blizzard Provides Update On Workplace Initiatives

Price Over Earnings Overview: Crane

Why PayPal Shares Are Falling Today